Amendments to the Claims:

Please amend claims 1, 10-12, 23, and 24 as shown in the listing of claims.

Please cancel claims 7-9, 25, and 27 without prejudice.

This listing of claims will replace all prior versions, and listings of claims in the application.

Listing of Claims:

1. (Currently Amended) A method for treating ~~a pathological condition of ocular tissue,~~ herpes simplex virus-1 (HSV-1) or cytomegalovirus (CMV) retinitis comprising ~~contacting a therapeutically active complex with ocular tissue, wherein the therapeutically active complex is 1-O-hexadecyloxypropyl-phospho-arabinofuranosylguanosine (HDP-P-Ara-G),~~ intravitreally injecting a suspension of particles of 1-O-hexadecylcycloxypropyl-cyclic-cidofovir (HDP-cCDV) or particles of hexadecyloxypropyl-3-phosphoganciclovir (HDP-P-GCV) to the eye, wherein the ~~pathological condition is selected from the group consisting of macular degeneration, ocular proliferative or vascular diseases, and diseases of elevated intraocular pressure thereby treating the pathological condition~~ wherein the HDP-cCDV and the HDP-P-GCV particles have a size of about 10 nm to 100,000 nm and wherein the particles are not liposomes.

2-9. (Canceled).

10. (Currently Amended) The method of claim 1, wherein the ~~therapeutically active complex is in a slurry comprising~~ particles of HDP-cCDV and the particles of HDP-P-GCV are in amorphous forms and/or crystalline forms.

11. (Currently Amended) The method of claim 1, wherein the ~~therapeutically active complex is~~ particles of HDP-cCDV and the particles of HDP-P-GCV are in ~~substantially~~ crystalline form.

12. (Currently Amended) The method of claim 1, wherein the ~~therapeutically active complex is~~ particles of HDP-cCDV and the particles of HDP-P-GCV are in ~~substantially~~ amorphous form.

13-22. (Canceled).

23. (Currently Amended) A method for the slow-release delivery of ~~a therapeutically active agent to ocular tissue, comprising contacting the ocular tissue with a therapeutically active complex, wherein the therapeutically active complex is~~ 1-O-hexadecyloxypropyl-phospho-arabinofuranosyl-guanosine (HDP-P-Ara-G), 1-O-hexadecylcycloxypropyl-cyclic-cidofovir (HDP-cCDV) or hexadecyloxy-propyl-3-phospho-ganciclovir (HDP-P-GCV) to the eye, comprising intravitreally injecting a suspension of particles of HDP-P-Ara-G, or particles of HDP-cCDV or particles of HDP-P-GCV to the eye, wherein the ~~therapeutically active complex comprises particles having size between about 10 nm and about 100,000 nm, thereby delivering a slow-release of the therapeutically active agent to ocular tissue~~ wherein the HDP-cCDV and the HDP-P-GCV particles have a size of about 10nm to 100,000nm and wherein the particles are not liposomes.

24. (Currently Amended) A method for increasing residence time of ~~a therapeutically active agent in ocular tissue, comprising contacting a therapeutically active complex with ocular tissue, wherein the therapeutically active complex is~~ 1-O-hexadecyloxypropyl-phospho-arabinofuranosylguanosine (HDP-P-Ara-G), 1-O-hexadecylcycloxypropyl-cyclic-cidofovir (HDP-cCDV) or hexadecyloxypropyl-3-phospho-ganciclovir (HDP-P-GCV) in the eye, ~~thereby increasing residence time of the therapeutically active agent in ocular tissue~~ comprising intravitreally injecting a suspension of particles of HDP-P-Ara-G, particles of HDP-P-cCDV or particles of HDP-GCV to the eye, wherein the particles have a size of about 10nm to 100,000nm and wherein the particles are not liposomes.

25-63. (Canceled).